Wednesday, June 10, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 10 of 1,261
  1. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  2. US 12428376

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  3. US 12426594

    Cryoprotective compositions and methods for protection of a surgical site during cryosurgery

    Regents of the University of Minnesota Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  4. US 12427201

    Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

    Sutro Biopharma, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  6. US 12428395

    Heterocyclic compounds as kinase inhibitor and uses thereof

    SPEROGENIX THERAPEUTICS LIMITED Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  7. US 12428379

    Acylsulfonamide KAT6A inhibitors

    Olema Pharmaceuticals, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  8. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  9. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  10. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  11. US 12427212

    Nectin-4 binding miniproteins, conjugates and uses thereof

    Aktis Oncology, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  12. US 12427170

    Universal donor cells

    CRISPR THERAPEUTICS AG Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  13. US 12428470

    Compositions containing activatable antibodies

    CytomX Therapeutics, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  14. US 12427121

    Enhanced delivery epinephrine compositions

    Aquestive Therapeutics, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  15. US 12428480

    Anti-CD19 antibodies and multi-specific binding proteins

    Cullinan Therapeutics, Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  16. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  17. US 12427160

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  18. US 12427132

    Method of improving sleep

    VANDA PHARMACEUTICALS INC. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  19. US 12427111

    Lipid nanoparticles

    CodeBridgeBio Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  20. US 12428408

    Fused heterocyclic mescaline derivatives

    Enveric Biosciences Canada Inc. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  21. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  22. US 12427171

    Krill oil composition enriched in LPC-DHA and LPC-EPA

    Aker BioMarine Human Ingredients AS Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  23. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted
  24. US 12428406

    Methods and compounds for restoring mutant p53 function

    PMV PHARMACEUTICALS, INC. Β· Granted Sep 30, 2025 Β· Expires Sep 25, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.